1Barrett NR.Chronic peptic ulcer of the oesophagus and "oesophagitis".Br J Surg,1950,38(2):175-182.
2Swami S,Kumble S,Triadafilopoulos G.E-cadherin expression in gstroesophageal reflux disease,Barrett's esophagus,and esophageal adenocarcinoma:an immunohistochemical and immunoblot study.Am J Gastroenterol.1995,90(10):1808-1813.
3Hamelin R,Flejou JF,Muzeau F,et al.TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus.Gastroenterology,1994,107(4):1012-1018.
4Walch A,Specht K,Bink K,et al.Her-2/neu gene amplification,elevated mRNA expression and protein overexpression in the metaplasia-dysplasiaadenocarcinoma sequence of Barrett's esophagus.Lab Invest,2001,81 (6):791-801.
5Walch AK,Zitzelsberger HF,Bruch et al.Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence.Am J Pathol,2000,156(2):555-566.
6Palanca-Wessels MC,Barrett MT,Galipeau PC,et al.Genetic analysis of long-term Barrett esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities.Gastroenterology,1998,114(2):295-304.
7Sampliner RE.Practice guidelines on the diagnosis,surveillance,and therapy of Barrett's esophagus.The Practice Parameters Committee of the American College of Gastroenterology.Am J Gastroenterol,1998,93 (7):1028-1032.
8Hayward J.The lower end of the oesophagus.Thorax 1961; 16 (1):36-41.
9Spechler SJ.Zeroogian JM,Antonioli DA et al.Prevalence of metaplasia at the gastro-oesophageal junction.Lancet,1994,344(8936):1533-1536.
10Polkowski W,van Lanschot JB,ten Kate FJW,et al.Prevalence of metaplasia at the gastro-oesophageal junction.Lancet,1994,344(8936):1533-1536.
二级参考文献5
1Couvelard A, Cauvin JM, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut, 2001,49:761-766.
2Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol, 2001,25:87-94.
3Flucke U, Steinborn E, Dries V, et al. Immunoreactivity of cytokeratins(CK7,CK20) and mucin peptide core antigens(MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stom
4Ormsby AH, Goldblum JR, Rice TW, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol, 1999,30:288-294.
5Chu PG, Jiang Z, Weiss LM. Hepatocyte antigen as a marker of intestinal metaplasia. Am J Surg Pathol, 2003,27:952-959.
6Spechler S J, Robbins AH, Rubins HB, et al. Adenocarcinoma and Brarrett's esophagus. Anoverrated Risk [ J]. Gastroenteroloy, 1998,87 : 927 - 933.
7Fortun PJ, Anagnostopoulos GK, Kaye P, et al. Acetic acid - enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia,dysplasia and early cancer in Barrett's oesophagus [ J]. Aliment Pharmacol Ther, 2006,23:735 - 742.
8James R, Erler T, Kazenwadel J. Structure of the murine homeobox gene CDX2 : Expression in embryonic and adult intestinal epithelium[ J]. J Biol Chem, 1994,26.9 : 15229 - 15237.
9Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin : an immunohistochemical survey of 476 primary and metastatic carcinomas [J]. Am J Surg Pathol,2003 ,27 :303 - 310.
10Eda A, Osawa H, Yanaka I, et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia[J]. J Gastroenterol,2002,37:94 - 100.
